RU2018139523A3 - - Google Patents

Download PDF

Info

Publication number
RU2018139523A3
RU2018139523A3 RU2018139523A RU2018139523A RU2018139523A3 RU 2018139523 A3 RU2018139523 A3 RU 2018139523A3 RU 2018139523 A RU2018139523 A RU 2018139523A RU 2018139523 A RU2018139523 A RU 2018139523A RU 2018139523 A3 RU2018139523 A3 RU 2018139523A3
Authority
RU
Russia
Application number
RU2018139523A
Other languages
Russian (ru)
Other versions
RU2747258C2 (ru
RU2018139523A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018139523A publication Critical patent/RU2018139523A/ru
Publication of RU2018139523A3 publication Critical patent/RU2018139523A3/ru
Application granted granted Critical
Publication of RU2747258C2 publication Critical patent/RU2747258C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018139523A 2016-04-10 2017-04-10 Комбинированные способы терапии для лечения злокачественной опухоли RU2747258C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
US62/320,549 2016-04-10
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021110230A Division RU2021110230A (ru) 2016-04-10 2017-04-10 Комбинированные способы терапии для лечения злокачественной опухоли

Publications (3)

Publication Number Publication Date
RU2018139523A RU2018139523A (ru) 2020-05-15
RU2018139523A3 true RU2018139523A3 (cg-RX-API-DMAC7.html) 2020-07-07
RU2747258C2 RU2747258C2 (ru) 2021-04-29

Family

ID=58794130

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2021110230A RU2021110230A (ru) 2016-04-10 2017-04-10 Комбинированные способы терапии для лечения злокачественной опухоли
RU2018139523A RU2747258C2 (ru) 2016-04-10 2017-04-10 Комбинированные способы терапии для лечения злокачественной опухоли

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2021110230A RU2021110230A (ru) 2016-04-10 2017-04-10 Комбинированные способы терапии для лечения злокачественной опухоли

Country Status (14)

Country Link
US (2) US11278555B2 (cg-RX-API-DMAC7.html)
EP (1) EP3442582A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019510807A (cg-RX-API-DMAC7.html)
KR (2) KR20190008206A (cg-RX-API-DMAC7.html)
CN (2) CN118304400A (cg-RX-API-DMAC7.html)
AU (2) AU2017250732B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018070847A2 (cg-RX-API-DMAC7.html)
CA (1) CA3020067A1 (cg-RX-API-DMAC7.html)
IL (1) IL262191B2 (cg-RX-API-DMAC7.html)
MX (2) MX390751B (cg-RX-API-DMAC7.html)
RU (2) RU2021110230A (cg-RX-API-DMAC7.html)
SG (1) SG11201808849TA (cg-RX-API-DMAC7.html)
WO (1) WO2017179053A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201807187B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
CN106458190B (zh) 2014-05-30 2019-12-06 戴科知识产权控股有限责任公司 具有喷射器、气动控制阀和可选择的吸气器的真空创建系统
WO2019116376A1 (en) * 2017-12-17 2019-06-20 Yeda Research And Development Co. Ltd. Cop9 signalosome (csn) complex modulators and uses thereof
WO2022149934A1 (ko) * 2021-01-08 2022-07-14 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL201172B1 (pl) 1998-12-09 2009-03-31 Yeda Res & Dev Pd-Bakteriofeoforbid, sposób jego wytwarzania, kompozycja farmaceutyczna zawierająca go i jego zastosowanie
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
AU2009305893B2 (en) 2008-10-23 2014-03-27 Steba Biotech S.A. RGD-containing peptidomimetics and uses thereof
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
TWI442945B (zh) * 2011-05-18 2014-07-01 Univ Nat Taiwan 雙效微脂體用於治療的方法
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Also Published As

Publication number Publication date
MX2022003190A (es) 2022-04-11
EP3442582A1 (en) 2019-02-20
BR112018070847A2 (pt) 2019-02-05
RU2747258C2 (ru) 2021-04-29
US20190125769A1 (en) 2019-05-02
MX390751B (es) 2025-03-21
AU2017250732A1 (en) 2018-11-15
JP2022031823A (ja) 2022-02-22
SG11201808849TA (en) 2018-11-29
AU2017250732B2 (en) 2022-11-10
IL262191B2 (en) 2025-01-01
KR20190008206A (ko) 2019-01-23
IL262191A (en) 2018-11-29
IL262191B1 (en) 2024-09-01
CA3020067A1 (en) 2017-10-19
AU2023200591A1 (en) 2023-03-09
US20220202838A1 (en) 2022-06-30
JP2019510807A (ja) 2019-04-18
CN109862918A (zh) 2019-06-07
WO2017179053A1 (en) 2017-10-19
ZA201807187B (en) 2020-01-29
CN118304400A (zh) 2024-07-09
RU2018139523A (ru) 2020-05-15
RU2021110230A (ru) 2021-05-26
US11278555B2 (en) 2022-03-22
MX2018012392A (es) 2019-08-21
KR20220139445A (ko) 2022-10-14

Similar Documents

Publication Publication Date Title
BR112019002665A2 (cg-RX-API-DMAC7.html)
BR112018004986A2 (cg-RX-API-DMAC7.html)
BR112019001429A2 (cg-RX-API-DMAC7.html)
BR212018070320U2 (cg-RX-API-DMAC7.html)
BR112019008501B1 (pt) Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador
BR112019003116B1 (pt) Configuração de símbolo de rajada comum de uplink
BR112018076493B1 (pt) Sistemas e métodos para detecção de posição de feixe de luz
BR112018073794B1 (pt) Partícula, método de geração da partícula, vacina ou composição farmacêutica
BR122026002520A2 (pt) Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno
BR112019006736A2 (cg-RX-API-DMAC7.html)
CN303648210S (zh) 床用吸尘器(spd501)
CN303646517S (zh) 光电红外探测器(2)
CN303612009S (zh) 电源适配器(a116)
CN303634661S (zh) 支付机
CN303597607S (zh) 杯架(87006)
CN303538091S (zh) 柱式床(mk10)
CN303538222S (zh) 护颈枕(2)
CN303536045S (zh) 嫁衣(15)
CN303542549S (zh) 柴油机(1)
CN303537535S (zh) 车家床(四六分圆拉床半围)
CN303536111S (zh) 眼罩(条纹)
CN303536110S (zh) 眼罩(花纹)
CN303610945S (zh) 包装盒(红糖姜茶固体饮料)
CN303537405S (zh) 凳子(2076)
CN303597468S (zh) 水龙头喷管